Browse by author
Lookup NU author(s): Dr Chris PlummerORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© The Author(s) 2025.Over 1 million cases of prostate cancer are reported every year, and it is the second most common cancer in men. Androgen deprivation therapy (ADT) is a hallmark treatment for prostate cancer but is associated with the development or exacerbation of cardiovascular disease. The most common cause of non-cancer death in patients with prostate cancer is cardiovascular disease. Thus, a better understanding of the prevalence of cardiovascular toxicity across all therapies, management of potential cardiovascular complications, and prevention of cardiovascular events is essential as treatments continue to evolve. In this article, the first in a 2-part series, we provide a review of the current landscape of ADT therapy and its association with cardiovascular disease, summarize recent clinical trial data evaluating cardiovascular outcomes, and provide insights on the management of cardiovascular risk factors and adverse events for clinicians managing this high-risk population of men undergoing potentially cardiotoxic treatment for prostate cancer.
Author(s): Shah NP, Singh A, Higano T, Tilki D, Fleshner N, Nguyen P, Plummer C, Rivas JG, Zhang K, Rendon R, Morgans A, Cirne F, Leong D, Lenihan D, Lopes RD
Publication type: Letter
Publication status: Published
Journal: Cardio-Oncology
Year: 2025
Volume: 11
Issue: 1
Online publication date: 29/03/2025
Acceptance date: 07/02/2025
ISSN (electronic): 2057-3804
Publisher: BioMed Central Ltd
URL: https://doi.org/10.1186/s40959-025-00318-5
DOI: 10.1186/s40959-025-00318-5
Data Access Statement: No datasets were generated or analysed during the current study.
